Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is able to provide informed consent and must sign the Institutional Review Board approved Informed Consent Form;~* Is at least 21 years of age;~* Have central low back pain aggravated by movement and or postural changes (standing/sitting);~* Have had back pain for at least 6 months, and have failed conservative management~* One Grade III or IV (Pfirrmann Scale) degenerated lumbar disc;~Exclusion Criteria:~* Current disc extrusion at any level in their lumbar spine; disc bulges or protrusions at any level in the lumbar spine resulting in nerve root compression;~* Severe disc narrowing (equal to or more than 50% loss of disc height at the targeted level);~* Type II or III Modic changes at any level;~* Type I Modic changes at any level other than the targeted level;~* Type I Modic changes at the treated level if maximum height of the changes is 25% or more of the vertebral body height;~* Osteoporotic compression fracture at any vertebral level;~* Lumbar Scheurmann's disease;~* Antero or retrolisthesis ≥ 3mm at any level;~* Currently experiencing chronic pain generating from any other source, which (in the judgment of the investigator) may interfere with the evaluation of back pain, and or disability;~* Infection at the planned treatment site, history of systemic or local infection, which (in the investigator's judgment) may compromise subject participation and/or safety;~* Currently diagnosed with immune-deficiency, which in the investigator's opinion may compromise subject participation and/or safety;~* Receiving any immune-suppressant therapies other than short term steroid preparations;~* BMI≥40;~* Diagnosed with any comorbid conditions including: abnormal bleeding, AIDS, diabetes, hepatic or renal disease, and cardiopulmonary disorders such as COPD, MI and CHF; active malignancy or history of malignancy, or diseases of bone metabolism, which in the investigator's opinion may compromise subject participation and/or safety;~* Has a history of alcoholism, medication or intravenous drug abuse, psychosis, is a prisoner, has a personality disorder(s), poor motivation, emotional or intellectual issues that would likely make the subject unreliable for the study, or 3 or more Waddell Signs of nonorganic Behavior or any combination of variables in the Investigator's judgment that should exclude a potential subject;~* Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage, personal injury compensation or litigation claims;~* Has active or pending workers' compensation claims;~* Has contraindications for MRI.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NuQu treatment (Type: EXPERIMENTAL): single administration
- Saline (Type: OTHER): single administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy